Simple pee test could spare half of bladder cancer patients from failed treatments
NCT ID NCT04564781
Summary
This study is testing a new urine test that aims to predict whether bladder cancer patients will respond to standard BCG immunotherapy. Currently, about half of patients don't benefit from BCG treatment, leading to additional therapies or bladder removal surgery. The test measures immune markers in urine to identify patients who are likely to respond well before they start treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cedars-Sinai Medical Center
RECRUITINGLos Angeles, California, 90048, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Kyoto University
RECRUITINGKyoto, Kyoto, 606-8501, Japan
Contact
-
UCLA
RECRUITINGLos Angeles, California, 90095, United States
Contact
-
UCSF
RECRUITINGSan Francisco, California, 94143, United States
Contact
-
University of Texas Southwestern
RECRUITINGDallas, Texas, 75390, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.